Current & future perspectives in psychiatric drug discovery

12th March 2009
GlaxoSmithKline, New Frontiers Science Park, Harlow, Essex
Current & future perspectives in psychiatric drug discovery

Programme:

Psychiatric diseases, such as anxiety, depression and schizophrenia, remain a major cause of disability, affecting 300 million people worldwide. Pharmacotherapy has had a major impact on the management of those with psychiatric disorders, but the associated side-effects, along with efficacy that is less than complete, means that the need for safe and effective psychotherapeutic drugs remains high.

This symposium brings together experts across the breadth of research and development in this field and will provide talks covering both the current challenges and recent advances in the clinical setting including the application of new technologies as well as a number of case studies of important new approaches to treat psychiatric disorders.

09.30  Registration and coffee

**Session 1 - Chair: Eric Karran, Johnson & Johnson**

10.00  Cognitive enhancement in schizophrenia, depression and addiction: Prospects and pitfalls
**Trevor Robbins, Cambridge University, UK**

11.00  Cognition in animals: measurement and application to neuroscience drug discovery for schizophrenia
**Mark Tricklebank, Lilly, UK**

11.40  Development of a Neurology & Psychiatry Imaging Toolbox
**Ian Wilson, GE Healthcare Medical Diagnostics, UK**

12.20  Lunch

Register on-line at: [www.smr.org.uk](http://www.smr.org.uk)
Programme:

**Session 2 - Chair: Wendy Alderton, Summit plc**
13.20 Clinical perspective: new therapeutic approaches for treating Depression
Bob Alexander, GlaxoSmithKline

14.00 Smoking cessation: varenicline, an α4β2 partial agonist
Brian O’Neill, Pfizer, USA

14.50 Tea

**Session 3 - Chair: Simon Ward, GlaxoSmithKline**
15.20 A 'Fast' Track to Atypicality - The Discovery of JNJ37822681 for the Treatment of Schizophrenia
Gregor Macdonald, Johnson & Johnson Research and Early Development (RED) Europe, Belgium

16.00 PDE10 inhibitors for psychiatric disorders
Frank Menniti, Pfizer, USA

16.40 Close

---

**SMR Meetings in 2009**

**Optimising drugs for local delivery**
11th June 2009
Novartis institutes for Biomedical Research, Horsham, West Sussex

**Toxicities Encountered in Drug Discovery**
24th September 2009
NHLI, London

**SMR Award Meeting**
10th December 2009
NHLI, London
Current & future perspectives in psychiatric drug discovery

Name: ____________________________  (Incl. Title)
Address: ____________________________  (Incl. Company Name)
Tel: ____________________________  Fax: ____________________________
Email: ____________________________

Dietary Requirements:  [ ] Vegetarian:  Other: ____________________________

Registration Fees:
SMR members: £80  [ ]  Non-Members: £120  [ ]
Students:*  £35  [ ]  Retired members: £35  [ ]

*Students should attach a letter confirming their student status from their HoD/Supervisor to this booking form.

Payment Methods:

Cheque: If you wish to pay by cheque, then please send your cheque made payable to Society for Medicines Research, together with this form to the address given below.

Credit/Debit Card: To pay by Visa/Eurocard/MasterCard/Switch/Delta/ConnectCard or American Express simply enter your card details below.

Card Nr: ____________________________  Expiry Date: ____________________________
Cardholders address if different from above: ____________________________

Names and addresses of delegates will be included in a list given to all attendees. If you do NOT want your name to appear please tick this box. [ ]

Fees once paid are not refundable unless a cancellation is received at least 5 working days prior to the event. Delegate substitutes are permitted at any time.

Join on-line at www.smr.org.uk or through our secretariat at the address given below.

DATA PROTECTION ACT: By completing and returning this form you agree to allow the Society for Medicines Research to hold and process data about your registration on computer and to pass this information on to 3rd parties as may be required in order to provide the services being offered. The Society for Medicines Research does not rent or sell this data to other companies or organisations.